Diridavumab represents a highly specialized fully human broadly neutralizing monoclonal antibody specifically engineered to target the highly conserved stem region of the influenza A virus hemagglutinin with exceptional binding affinity and selectivity, effectively facilitating the measurable blockade of the pH-induced conformational change required for membrane fusion across various preclinical experimental models to evaluate the prophylactic efficacy against diverse influenza subtypes during strictly monitored laboratory observation periods.
CAS Nummer:
[1393659-46-5]
Target-Kategorie:
Influenza Virus
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
